spacer
home > ebr > spring 2019 > ecoa technology in vaccine clinical trials
PUBLICATIONS
European Biopharmaceutical Review

eCOA Technology in Vaccine Clinical Trials

Immunisation is one of the most successful and cost-effective public health interventions, protecting individuals against several serious, preventable, and sometimes, deadly contagious diseases, with a common example being the measles, mumps, and rubella vaccine. As essential as they are for preventative healthcare, vaccines are facing challenges in clinical trials and the industry is responsible for moving them faster through the process.

Vaccine developments face similar challenges to other therapeutic areas such as processing large volumes of manual data, which can be costly, time-consuming, and inefficient. Additionally, vaccine clinical trials often have aggressive timelines, and sponsors require a cost-effective and robust solution for data collection. By integrating electronic clinical outcome assessment (eCOA) with existing technologies, researchers can reduce the burden for study teams, increase patient compliance and retention, and improve overall study outcomes – quickly. Making the switch from traditional paperbased processes to an eCOA solution in a vaccine trial can offer many tangible benefits.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing and product development teams. Previously, Katie worked as a Project Manager for a Health Outcomes Consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, where she was responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement